Your SlideShare is downloading. ×
Molecular pharming
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Molecular pharming

1,609
views

Published on

Published in: Health & Medicine

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
1,609
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
146
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Molecular Pharming Presented by: C.G.O. Gaas Introduction to Biotechnology Chemical Engineering Department CIT-University
  • 2. Molecular Pharming History and Definition How is it done? Advantages and Disadvantages Examples and its Applications Biosafety Issues of Molecular Faming
  • 3. What is Molecular Pharming? The use of whole organisms, organs, tissues or cells, or cell cultures, as bio-reactors for the production of commercially valuable products via recombinant DNA techniques.
  • 4. Difference between Molecular pharming and Molecular farming Molecular pharming -It is defined as the production of active pharmaceutical substances in genetically modified organisms (GMOs). -Plants are preferred as plants do not carry pathogens. Still the safety of GMO is a concern. -First plant derived pharmaceutical protein is serum albumin. Molecular farming It is defined as the use of genetically modified organisms (GMOs) as a production platform for renewable raw materials, fine chemicals and dietary supplements
  • 5. History • 1986 First plant -derived recombinant therapeutic proteinhuman GH in tobacco & sunflower. (A. Barta, D. Thompson et al.) • 1989 First plant -derived recombinant antibody – full-sized IgG in tobacco. (A. Hiatt, K. Bowdish) • 1990 First native human protein produced in plants – human serum albumin in tobacco & potato. (P. C. Sijmons et al.) • 1992 First native human protein produced in plants – human serum albumin in tobacco & potato. (P. C. Sijmons et al.) • 1995 First plant derived industrial enzyme – α-amylase in tobacco. (J.Pen, L. Molendijk et al.)
  • 6. History • 1996 First plant derivedprotein polymer tobacco. (X. Zhang, D. W. Urry, H. Daniel) – artificial elastin • 1997 • 1997 Commercial production of avidin in maize.(E. E. Hood et al.) • 2000 • 2003 Human GH produced in tobacco chloroplast.(J. M. Staub et al.) Expression and assembly of a functional antibody in algae Commercial production of bovine trypsin in maize.(S. L. Woodard ) First clinical trial using recombinant bacterial delivered in a transgenic potato. (C. O. Tacket et al.) in antigen Human GH produced in tobacco chloroplast.(J. M. Staub et al.)
  • 7. How is it done? A DNA molecule carrying the genetic information for a pharmaceutical substance is introduced into the plant genome. This process (1) is called transformation. The genes can be incorporated permanently (stable transformation) or for a short period of time (transient transformation). The transformed plant acts as a bioreactor producing large quantities of the pharmaceutical using its protein making machinery (2). Through industrial processing, the pharmaceutically active substance is extracted from the plant (3) and made into in a formulated product (4), for example a pill.
  • 8. How is it done? Virus (left) with genetic material inside and surface proteins (green and orange) on the outside. Viruslike particle (on the right) without genetic material and some virus surface proteins (green)
  • 9. Pharming General Strategy • Clone a gene of interest • Transform the host platform species • Grow the host species, recover biomass • Process biomass • Purify product of interest • Deliver product of interest
  • 10. Comparison of different Pharming production systems
  • 11. Molecular Pharming and Farming Applications Parental therapeutics and pharmaceutical intermediates Industrial proteins and enzymes Biopolymers Monoclonal antibodies Antigens for edible vaccines
  • 12. Biosafety Issues on Pharming • Gene and Protein Pollution • Product Safety
  • 13. Transgene Pollution Transgene pollution is the spread of transgenes beyond the intended genetically-modified species by natural gene flow mechanisms. Two classes of transgene pollution: • The possible spread of primary transgenes. • The possible spread of superfluous DNA sequences.
  • 14. Transgene Pollution Mechanism Vertical gene transfer • Vertical gene transfer is the movement of DNA between plants that are at least partially sexually compatible. • Most prevalent form of transgene pollution. • Occurs predominantly via the dispersal of transgenic pollen/seed dispersal. Horizontal gene transfer • Horizontal gene transfer is the movement of genes between species that are not sexually compatible and may belong to very different taxonomic groups. • The process is common in bacteria (Agrobacterium tumefaciens and related species), resulting in the transfer of plasmid-borne antibiotic resistance traits. • Antibiotic resistance markers and transgenes encoding pharmaceutical proteins could be acquired by human pathogens.
  • 15. Product safety • The purified protein may be contaminated with toxic substances from the plant or applied to the plant, e.g. plant derived metabolites, allergens, field chemicals (e.g. herbicides, pesticides, fungicides), fertilizers, dung and manure. • The product itself, due to intrinsic properties, may be harmful.
  • 16. Transgene pollution –possible solutions • Minimum required genetic modification. • Elimination of non-essential genetic information. • Containment of essential transgenes. (Physical or artificial) -Maintained in green house -Concealing flowers/fruits in plastic bags in field -Isolation -Barrier crops • Alternative production systems -transient expression. -Plant suspension cultures in sealed, sterile reactor vessels. (Fischer et al., 1999a; Doran, 2000)
  • 17. Perspectives on Molecular Pharming • Use of virus infected plants is best approach for molecular farming • Molecular farming provides an opportunity for the economical and large-scale production of pharmaceuticals, industrial enzymes and technical proteins that are currently produced at great expense and in small quantities. • We must ensure that these benefits are not outweighed by risks to human health and the environment
  • 18. Thank you for listening. . . . 